SciSparc GERD acquisition boosts momentum as SPRC enters the device market, aiming to scale globally with innovative endoscopic technology.SciSparc GERD acquisition boosts momentum as SPRC enters the device market, aiming to scale globally with innovative endoscopic technology.

SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Scisparc Ltd. (Sprc) Stock: Jumps As Company Expands Into High-Growth Gerd Device Market

SPRC reported a notable stock rise today, with SciSparc trading at $3.0497 as of 10:40 AM EST. The strong increase highlights growing market confidence as SciSparc moves into the expanding GERD device segment. SPRC strengthens its position by advancing its strategy through a new intellectual property acquisition.

SciSparc Ltd. (Nasdaq: SPRC) Stock

SciSparc completed a binding term sheet with Xylo Technologies to obtain patents, trademarks and medical device rights. This action allows SciSparc to pursue commercialization of the MUSE endoscopic system, which supports minimally invasive GERD treatment. SciSparc aims to scale its reach by forming regional distribution agreements across high-growth territories.

The recent stock momentum reflects rising expectations for SciSparc as it diversifies beyond clinical-stage pharmaceutical activity. SPRC looks to build revenue streams through new medical technologies, reinforcing growth ambitions. SciSparc positions itself to capture value in a market expected to expand gradually.

Expansion Through Strategic Technology Acquisition

SPRC  plans to issue ordinary shares representing 19.99% of its capital to Xylo upon closing. The company may also opt to issue pre-funded warrants, providing flexibility during the transaction. The assets obtained include full ownership of the MUSE system and related intellectual property.

SciSparc expects to replicate Xylo’s prior commercialization structure to reach major medical markets. In 2019, Xylo secured $3 million upfront from a China licensing agreement, and SciSparc now seeks similar partnerships abroad. SciSparc targets North America, Europe and Latin America, where demand continues to rise.

The MUSE™ system is designed for transoral fundoplication, enabling GERD symptom relief through a non-surgical method. SciSparc anticipates increased adoption due to growing preference for minimally invasive procedures. This technology aligns with long-term healthcare trends focused on efficiency and patient recovery.

Market Outlook and Industry Context

According to industry research, the global GERD device market reached $2.5 billion in 2024. It is projected to reach $3.03 billion by 2030 at a CAGR of 3.24% from 2025. Consequently, SciSparc aligns with a sector demonstrating stable demand and gradual growth.

SciSparc’s expansion comes amid broader healthcare innovations targeting chronic digestive conditions. The company supports continued development through its majority-owned subsidiary, NeuroThera Labs Inc. This move signals SciSparc’s intent to extend beyond pharmaceuticals into high-value medical equipment.

SciSparc remains subject to completion of definitive agreements before finalizing the acquisition. The company maintains confidence in closing terms without regulatory complications. In the meantime, SciSparc continues advancing toward commercial readiness while capitalizing on current momentum.

Stock Performance and Strategic Position

SciSparc stock stabilized around $3.05 following initial volatility during market open. The trading surge indicates stronger recognition of the company’s new strategic direction. SPRC reinforces long-term positioning through technological expansion and wider geographic outreach.

SciSparc develops pharmaceutical candidates and now broadens ambitions within high-potential medical device markets. Its latest acquisition effort supports diversification and revenue acceleration. SPRC demonstrates proactive steps to strengthen competitiveness and market presence.

SciSparc plans further updates as negotiations progress and commercialization strategies unfold. The company remains focused on execution while maintaining regulatory compliance. SPRC moves forward with momentum as it transitions into the GERD device industry.

This article was originally published as SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market on Crypto Breaking News – your trusted source for crypto news, Bitcoin news, and blockchain updates.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump is running out of time — and Republicans ready to abandon him

Trump is running out of time — and Republicans ready to abandon him

When President Donald Trump was reelected in 2024, he rode in on a largely populist message that promised to lower prices, reduce inflation, cut taxes, and improve
Share
Alternet2026/03/23 22:02
One Of Frank Sinatra’s Most Famous Albums Is Back In The Spotlight

One Of Frank Sinatra’s Most Famous Albums Is Back In The Spotlight

The post One Of Frank Sinatra’s Most Famous Albums Is Back In The Spotlight appeared on BitcoinEthereumNews.com. Frank Sinatra’s The World We Knew returns to the Jazz Albums and Traditional Jazz Albums charts, showing continued demand for his timeless music. Frank Sinatra performs on his TV special Frank Sinatra: A Man and his Music Bettmann Archive These days on the Billboard charts, Frank Sinatra’s music can always be found on the jazz-specific rankings. While the art he created when he was still working was pop at the time, and later classified as traditional pop, there is no such list for the latter format in America, and so his throwback projects and cuts appear on jazz lists instead. It’s on those charts where Sinatra rebounds this week, and one of his popular projects returns not to one, but two tallies at the same time, helping him increase the total amount of real estate he owns at the moment. Frank Sinatra’s The World We Knew Returns Sinatra’s The World We Knew is a top performer again, if only on the jazz lists. That set rebounds to No. 15 on the Traditional Jazz Albums chart and comes in at No. 20 on the all-encompassing Jazz Albums ranking after not appearing on either roster just last frame. The World We Knew’s All-Time Highs The World We Knew returns close to its all-time peak on both of those rosters. Sinatra’s classic has peaked at No. 11 on the Traditional Jazz Albums chart, just missing out on becoming another top 10 for the crooner. The set climbed all the way to No. 15 on the Jazz Albums tally and has now spent just under two months on the rosters. Frank Sinatra’s Album With Classic Hits Sinatra released The World We Knew in the summer of 1967. The title track, which on the album is actually known as “The World We Knew (Over and…
Share
BitcoinEthereumNews2025/09/18 00:02
Trump twists himself in knots to explain why giving Iran money is different from Obama

Trump twists himself in knots to explain why giving Iran money is different from Obama

President Donald Trump spoke to reporters ahead of a trip to Memphis, Tennessee on Monday morning after spending the weekend in Palm Beach, Florida. Trump took
Share
Alternet2026/03/23 22:38